4 - Pluri Inc. (0001158780) (Issuer)
4 - Pluri Inc. (0001158780) (Issuer)
4 - Pluri Inc. (0001158780) (Issuer)
HAIFA, Israel, July 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote global wellbeing and sustainability, today announced it has signed a tech transfer and manufacturing agreement with Kadimastem Ltd. (TASE: KDST), a clinical stage biotechnology company developing therapeutic cells for ALS and diabetes treatments. PluriCDMO™, launched earlier this year, leverages Pluri's 47,000 square foot good manufacturing practice (GMP) cell production facility to manufacture cell-based products for life science companies. PluriCDMO™ will manufacture two cell therapy product can
HAIFA, Israel, July 08, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), which transforms cells into solutions that promote global wellbeing and sustainability, has announced a strategic proof of concept ("POC") agreement with a leading international agriculture corporation. The agreement is intended to boost the global vegetable product supply, streamline supply chains, and combat global climate change while ensuring a natural and more sustainable future for agriculture. The collaboration leverages the strengths of both companies—Pluri's extensive expertise in cell-expansion technologies and cellular agriculture compl
$10 million funding round from U.S. and EU strategic investors, will accelerate growth and empower efficient cultivated meat, fish and seafood production at global scale, potentially tackling significant scalability challenges faced by the cultivated food industry Round led by global corporates with significant equipment, manufacturing, supply chain, and product development experience, alongside a second investment from Tnuva Group, Pluri and additional investors"Ever After Foods' unique and innovative production platform empowered the change to our business model. The shift to a technology enabler will allow us to serve more players in the value chain," said Eyal Rosenthal, Chief Executi
10-K - Pluri Inc. (0001158780) (Filer)
8-K - Pluri Inc. (0001158780) (Filer)
8-K - Pluri Inc. (0001158780) (Filer)
Leading biotechnology company Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote global wellbeing and sustainability, today announced it has signed a tech transfer and manufacturing agreement with Kadimastem Ltd. (TASE: KDST), a clinical stage biotechnology company developing therapeutic cells for ALS and diabetes treatments. PluriCDMO™, launched earlier this year, leverages Pluri's 47,000 square foot good manufacturing practice (GMP) cell production facility to manufacture cell-based products for life science companies. PluriCDMO™ will manufacture two cell therapy product candidates for Kadimastem: AstroRx®, clinical grade
Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), which transforms cells into solutions that promote global wellbeing and sustainability, has announced a strategic proof of concept ("POC") agreement with a leading international agriculture corporation. The agreement is intended to boost the global vegetable product supply, streamline supply chains, and combat global climate change while ensuring a natural and more sustainable future for agriculture.
HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced the appointment of attorney James Roosevelt, Jr. to the Company's Advisory Board. Having served in public-service positions in Washington, D.C., followed by a successful decade in the private sector as CEO of Tufts Health Plan, Mr. Roosevelt is a trusted and sought-after advisor on business matters, legislative and regulatory issues, governance, and personnel matters. The intersection of public policy and health is a passion for him. As CEO of
HAIFA, Israel, July 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today announced the appointment of Lorne Abony to the Company's Board of Directors, effective as of July 11, 2023. Abony is a successful entrepreneur who has decades of experience building and scaling multi-billion-dollar global businesses – both public and private companies – across multiple industries. He is a globally recognized leader who has invested, directly or indirectly, in more than 20 cellular agriculture and cultivated food companies. Bringing his expertise t
SC 13G/A - Pluri Inc. (0001158780) (Subject)
SC 13G/A - Pluri Inc. (0001158780) (Subject)
SC 13G/A - Pluri Inc. (0001158780) (Subject)